Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites

• Main Authors: Zahra Khalaj (Author), Zohreh Baratieh (Author), Parvaneh Nikpour (Author), Matthias Schwab (Author), Elke Schaeffeler (Author), Fariborz Mokarian (Author), Hossein Khanahmad (Author), Rasoul Salehi (Author), Thomas E. Mürdter (Author), Mansoor Salehi (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: The polymorphic enzyme cytochrome P450 2D6 (CYP2D6) catalyzes a major step in the bioactivation of tamoxifen. Genotyping of clinically relevant CYP2D6 alleles and subsequent dose adjustment is a promising approach to individualize breast cancer therapy. The aim of this study was to inv...